\-\ Texto\\:\\ \ \(0\)\
\-\ tc\\-99m\\ mdp\\ bone\\ scan\\ demonstrates\\ diffusely\\ increased\\ uptake\\ in\\ the\\ axial\\ skeleton\\ as\\ well\\ as\\ parts\\ of\\ the\\ appendicular\\ skeleton\\.\\ \\ the\\ kidneys\\ and\\ soft\\ tissue\\ activity\\ are\\ not\\ visualized\\.\\ \\ these\\ findings\\ are\\ consistent\\ with\\ a\\ superscan\\,\\ secondary\\ to\\ diffuse\\ osteoblastic\\ metastatic\\ disease\\ in\\ a\\ patient\\ with\\ known\\ prostate\\ cancer\\.\ \(0\)\
\-\ superscan\\ \\-\\-\\ diffuse\\ osteoblastic\\ metastasis\\ \\-\\ prostate\\ cancer\\.\ \(0\)\
\-\ metabolic\\ and\\ myeloproliferative\\ disorders\ \(1\)\
\-\ 70\\ year\\ old\\ male\\ with\\ a\\ history\\ of\\ prostate\\ cancer\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ superscan\\:\\ 0\\.2030764772446944\ \(0\)\
\-\ prostate\\:\\ 0\\.17916522256383327\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.1442977345734551\ \(0\)\
\-\ skeleton\\:\\ 0\\.13768419698711548\ \(0\)\
\-\ cancer\\:\\ 0\\.11088810254071442\ \(0\)\
\-\ myeloproliferative\\:\\ 0\\.10687330583429674\ \(0\)\
\-\ parts\\:\\ 0\\.07796245613250438\ \(0\)\
\-\ mdp\\:\\ 0\\.07725104532631655\ \(0\)\
\-\ appendicular\\:\\ 0\\.07593415771372466\ \(0\)\
\-\ diffuse\\:\\ 0\\.06807914264145565\ \(0\)\
\-\ tc\\-99m\\:\\ 0\\.0642591156742391\ \(0\)\
\-\ diffusely\\:\\ 0\\.05678564149521359\ \(0\)\
\-\ metabolic\\:\\ 0\\.05553156018199879\ \(0\)\
\-\ 70\\:\\ 0\\.054026160824396895\ \(0\)\
\-\ disorders\\:\\ 0\\.053791192174396804\ \(0\)\
\-\ kidneys\\:\\ 0\\.05174626975500167\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.05164696441769401\ \(0\)\
\-\ visualized\\:\\ 0\\.04551226512229586\ \(0\)\
\-\ uptake\\:\\ 0\\.044670834535450156\ \(0\)\
\-\ activity\\:\\ 0\\.04218482406291498\ \(0\)\
\-\ metastasis\\:\\ 0\\.04208878060920956\ \(0\)\
\-\ known\\:\\ 0\\.03557961953241868\ \(0\)\
\-\ as\\:\\ 0\\.034015197523529675\ \(0\)\
\-\ axial\\:\\ 0\\.032089361527208836\ \(0\)\
\-\ scan\\:\\ 0\\.03147725605832866\ \(0\)\
\-\ secondary\\:\\ 0\\.03143460482248431\ \(0\)\
\-\ are\\:\\ 0\\.030654575592884255\ \(0\)\
\-\ these\\:\\ 0\\.029261114367866315\ \(0\)\
\-\ metastatic\\:\\ 0\\.028304071100211714\ \(0\)\
\-\ bone\\:\\ 0\\.027939930019208813\ \(0\)\
\-\ consistent\\:\\ 0\\.02756971406356846\ \(0\)\
\-\ increased\\:\\ 0\\.027506378707890206\ \(0\)\
\-\ soft\\:\\ 0\\.027380615315704605\ \(0\)\
\-\ tissue\\:\\ 0\\.02665027879542886\ \(0\)\
\-\ well\\:\\ 0\\.025435275696955934\ \(0\)\
\-\ demonstrates\\:\\ 0\\.02456080528491034\ \(0\)\
\-\ \\-\\:\\ 0\\.024101690246162676\ \(0\)\
\-\ findings\\:\\ 0\\.02393206494460473\ \(0\)\
\-\ male\\:\\ 0\\.020331651814308856\ \(0\)\
\-\ disease\\:\\ 0\\.018378125542311895\ \(0\)\
\-\ not\\:\\ 0\\.01624761410186757\ \(0\)\
\-\ a\\:\\ 0\\.015655255334944787\ \(0\)\
\-\ history\\:\\ 0\\.01552913865404057\ \(0\)\
\-\ year\\:\\ 0\\.012580332490433088\ \(0\)\
\-\ old\\:\\ 0\\.011512297327134928\ \(0\)\
\-\ patient\\:\\ 0\\.011270946459426157\ \(0\)\
\-\ in\\:\\ 0\\.011089400793164603\ \(0\)\
\-\ to\\:\\ 0\\.005619317216355082\ \(0\)\
\-\ the\\:\\ 0\\.005457208606722071\ \(0\)\
\-\ and\\:\\ 0\\.0047370790982162745\ \(0\)\
\-\ with\\:\\ 0\\.0046185858982851205\ \(0\)\
\-\ \\,\\:\\ 0\\.003561974546280097\ \(0\)\
\-\ of\\:\\ 0\\.003065889494683906\ \(0\)\
\-\ \\.\\:\\ 0\\.0018683966367024354\ \(0\)\
